Tag: iShares Biotechnology ETF

We’re booking a five-fold profit on one of drug stock’s rally to record highs

Eli Lilly takes weight-loss pill battle global with first Foundayo approval outside U.S.

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

Many bought this stock to play the GLP-1 boom, but it has bigger opportunities to boost its share price

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

The market for psychedelic drugs to treat mental health conditions gets a big buy signal

Buy the contractor before the renovation is complete: This stock’s next growth phase is taking shape

J&J falls despite a beat-and-raise quarter. Why we’re raising our price target anyways

Biotech’s recovery isn’t a ‘head fake.’  These 3 stocks could lead the next leg up